Update on amyloidosis: a roundtable discussion - 5PM
Agenda
Amyloidosis is a heterogeneous disease that can be acquired or hereditary. The disease can be localized or systemic, with amyloid accumulating in liver, spleen, kidney, heart, nerves, and/or blood vessels causing different clinical syndromes including cardiomyopathy, hepatomegaly, proteinuria, macroglossia, autonomic dysfunction, ecchymoses, neuropathy, renal failure, hypertension, and corneal and vitreous abnormalities. This broadcast will focus on light-chain (AL) amyloidosis which is the most common systemic amyloidosis. Because of the progressive nature of the disease, early diagnosis to prevent end-stage organ damage is vital. The expert faculty will discuss how an accurate diagnosis is the basis for appropriate therapy that is risk-adapted and response-tailored. They will describe current treatment approaches and will evaluate new targeted therapies, including updates from the XVIth International Symposium on Amyloidosis being held 26-29 March 2018 in Japan.
Learning objective
After participating in
this broadcast, you should be able to:
Describe the optimal management of
patients with amyloidosis
Agenda
17.00-17.20 Diagnosis
and prognostication
17.20-17.40 Current treatment
of AL amyloidosis
17.40-18.00 The
potential role of targeted therapies in the future management of AL amyloidosis